Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) and Encourages Investors Who Suffered Losses to Contact the Firm

Fulcrum stock halved after FDA concerns forced its lead drug's discontinuation.

What the company is saying

Fulcrum Therapeutics announced it is discontinuing its pociredir program for sickle cell disease, citing 'heightened FDA concerns' about the drug's benefit-risk profile. The company attributes the decision to FDA feedback following safety issues with Tazverik (tazemetostat), another PRC2 inhibitor, which was withdrawn globally in March 2026 due to secondary hematologic malignancies. Fulcrum states that the FDA concluded all PRC2-targeting drugs carry equivalent malignancy risks, regardless of subunit. The announcement explicitly says there is 'no viable regulatory path forward' for pociredir. The tone is factual and somber, with no attempt to reframe the news positively or to highlight alternative programs. The press release also notes that law firm Kaplan Fox & Kilsheimer LLP is investigating potential securities violations, but provides no detail on the scope or basis of this investigation.

What the data suggests

The only quantitative data disclosed are stock prices before and after the announcement: $6.42 per share at close on June 1, 2026, and $3.14 per share at close on June 2, 2026. This $3.28 per share drop represents a 51.09% decline in a single trading day, directly following the discontinuation news. No other financial metrics—such as cash position, burn rate, or alternative pipeline assets—are provided. The data is internally consistent and clearly links the regulatory setback to immediate market value destruction. No evidence is presented to support the company's claims about the FDA's rationale beyond the reference to Tazverik's withdrawal. The announcement lacks any forward-looking financial guidance or operational detail, making it impossible to assess the company's ability to recover or pivot.

Analysis

The announcement is factual and focused on the discontinuation of Fulcrum Therapeutics' pociredir program due to regulatory concerns, with a clear and immediate negative impact on the company's stock price. There is no promotional or exaggerated language; the tone is somber and reactive, not aspirational. The only forward-looking statement is the assertion that there is 'no viable regulatory path forward,' which is a negative projection rather than an inflated claim. No future benefits, milestones, or capital-intensive projects are discussed, and there is no attempt to reframe the setback as an opportunity. The data provided (stock price decline, regulatory rationale) is specific and directly tied to realised events. No profitability or operational growth metrics are disclosed, but the context is not one of growth or hype.

Risk flags

• ●Regulatory risk has fully materialized, with the FDA's safety concerns leading to the complete discontinuation of Fulcrum's lead program. This eliminates any near-term pathway to product approval or revenue from pociredir.
• ●Pipeline concentration risk is acute, as the announcement provides no information about other clinical assets or diversification, raising the possibility that pociredir was the company's primary or only value driver.
• ●Disclosure risk is present because the company does not provide details on financial runway, alternative programs, or contingency plans, leaving investors with no basis to assess future prospects.
• ●Legal risk is heightened by the announcement of an investigation by Kaplan Fox & Kilsheimer LLP into potential securities violations, which could result in litigation, financial penalties, or further reputational harm.

Bottom line

Fulcrum Therapeutics has lost its lead drug candidate after the FDA determined that all PRC2 inhibitors carry unacceptable malignancy risks, mirroring the recent global withdrawal of Tazverik. The stock price halved overnight, reflecting the market's view that pociredir was central to Fulcrum's value proposition. No alternative programs, financial details, or recovery plans are disclosed, leaving investors with no visibility into what—if anything—remains of the company's pipeline or cash position. The simultaneous announcement of a securities investigation compounds uncertainty and risk. Without new disclosures on remaining assets or a credible strategic pivot, the investment case is severely impaired. The most important takeaway is that Fulcrum's core value proposition has been eliminated, and the company now faces both operational and legal headwinds with no clear path forward.

Announcement summary

(NASDAQ: FULC) Fulcrum Therapeutics announced the discontinuation of its pociredir program for the treatment of SCD (sickle cell disease) on June 1, 2026, after market close. The company cited "heightened FDA concerns regarding pociredir's benefit-risk profile in SCD" due to "an unexpectedly high rate of secondary hematologic malignancies observed with Tazverik® (tazemetostat), another PRC2 inhibitor, which was withdrawn from the global market in March 2026." The FDA concluded that "any pharmacological intervention targeting the PRC2 complex carries equivalent malignancy risk regardless of the specific subunit engaged." As a result, Fulcrum Therapeutics stated it has "no viable regulatory path forward for further clinical development of pociredir." Following this news, the price of Fulcrum Therapeutics stock declined from a closing price on June 1, 2026 of $6.42 per share to close at $3.14 per share on June 2, 2026, a decline of $3.28 per share, or by 51.09%. Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics.

Disagree with this article?